The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net Unrealized Gains (Losses) | | Benefit Plans | | | | | Foreign currency translation adjustments | | Derivative financial instruments | | Actuarial gains (losses) and prior service (costs) credits | | Total | | | (U.S. $ in millions) | | | | | | | | | | | Balance as of December 31, 2025, net of taxes | | $ | (2,152) | | | $ | (199) | | | $ | (39) | | | $ | (2,391) | | | Other comprehensive income (loss) before reclassifications | | (131) | | | (35) | | | — | | | (167) | | | Amounts reclassified to the statements of income | | — | | | 13 | | | (2) | | | 11 | | | Release of cumulative translation adjustments | | (6) | | | — | | | — | | | (6) | | | Net other comprehensive income (loss) before tax | | (137) | | | (23) | | | (2) | | | (162) | | | Corresponding income tax | | (3) | | | — | | | — | | | (3) | | | Net other comprehensive income (loss) after tax | | (140) | | | (23) | | | (2) | | | (165) | | | Balance as of September 30, 2026, net of taxes | | $ | (2,292) | | | $ | (222) | | | $ | (41) | | | $ | (2,556) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net Unrealized Gains (Losses) | | Benefit Plans | | | | | Foreign currency translation adjustments | | Derivative financial instruments | | Actuarial gains (losses) and prior service (costs) credits | | Total | | | (U.S. $ in millions) | | | | | | | | | | | Balance as of December 31, 2024, net of taxes | | $ | (2,857) | | | $ | (238) | | | $ | (52) | | | $ | (3,148) | | | Other comprehensive income (loss) before reclassifications | | 509 | | | — | | | — | | | 509 | | | Amounts reclassified to the statements of income | | — | | | 30 | | | (2) | | | 28 | | | Release of cumulative translation adjustments** | | 181 | | | — | | | — | | | 181 | | | Net other comprehensive income (loss) before tax | | 690 | | | 30 | | | (2) | | | 718 | | | Corresponding income tax | | (45) | | | — | | | — | | | (45) | | | Net other comprehensive income (loss) after tax* | | 645 | | | 30 | | | (2) | | | 673 | | | Balance as of September 30, 2025, net of taxes | | $ | (2,212) | | | $ | (208) | | | $ | (54) | | | $ | (2,475) | |
__________ * Amounts do not include a $27 million gain from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests. ** In connection with the sale of Teva’s business venture in Japan.
|